• Textsize Middle
  • Textsize Large






Division of Clinical Health Science

Subject Clinical Health Science/Medical Science/Clinical Oncology
Ryuya Yamanaka
Assistant Professor   Yasuo Takashima
Postdoctoral Fellow & Secretary   Azusa Hayano
Research Resident   Saori Tamura
Research Contents We are aiming to develop novel diagnostic and therapeutic strategy for brain tumor by revealing prognostic marker, biomarker and target molecule based on genome analysis. We are also interested in the research areas of clinical health science, clinical oncology and medical genetics.
  1. Takashima Y, Sasaki Y, Hayano A, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, Tokino T, Yamanaka R:Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. Oncotarget 9(44):27471-27486, 2018. 
  2. Takashima Y, Kawaguchi A, Kanayama T, Hayano A, Yamanaka R: Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Oncotarget 9(27): 19065-19078, 2018.
  3. YamanakaR, Hayano A, Kanayama T: Radiation-induced gliomas: A comprehensive review and meta-analysis. Neurosurg Rev41(3):719-731, 2018.
  4. YamanakaR, Morii K, ShinboY, SanoM,HommaJ, Tsuchiya  N, Yajima N, TsukamotoY, Ogura R, NatsumedaM,AokiH, AkiyamaK, SaitohT, Tamura T, Hondoh H, KawaguchiA, TakahashiH,and Fujii Y : Late relapse of primary central nervous system lymphoma. Leukemia Lymphoma 58(2):475-477, 2017.
  5. YamanakaR, Hayano A: Radiation-induced sarcomas of the central nervous system: a systematic review. World Neurosurg 98:818-828, 2017.
  6. Koyama-NasuR, HayashiT, Nasu-Nishimura Y,AkiyamaT and Yamanaka R:Thr160 of Axin1 is critical for the formation and function of the beta-catenin destruction complex. Biochemical Biophysical Res Comm 459(3):411-415, 2015.
  7. KawaguchiA, YajimaN, TsuchiyaN, HommaJ, SanoM, NatsumedaM, TakahashiH, FujiiY, KakumaT, YamanakaR: Gene expression signature-based prognostic risk score in patients with glioblastoma. Cancer Sci 104(9):1205-1210, 2013.
  8. Kawaguchi A, Iwadate Y, Komohara Y, Sano M, Kajiwara K, Yajima N, Tsuchiya N, Homma J, Aoki H, Kobayashi T, Sakai Y, Hondoh H, Fujii Y, Kakuma T, Yamanaka R: Gene expression signature–based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res18(20):5672-5781, 2012.
  9. KawaguchiA, YajimaN, KomoharaY, AokiH, TsuchiyaN, HommaJ, SanoM, NatsumedaM, UzukaT, SaitohA, TakahashiH, SakaiY, TakahashiH, FujiiY, KakumaT, YamanakaR: Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients.  Int J Oncol 40(3):721-730, 2012.
  10. YamanakaR, Saya H: Molecularly targeted therapies for glioma. Ann Neurol 66:717-729, 2009.
  11. Li J, Okamoto H, Yin C, Takizawa J,Aoki S,Gläsker S, Rushing EJ, Vortmeyer AO, Oldfield EH,Yamanaka R,Zhuang Z: Proteomic characterization of primary CNS diffuse large B-cell lymphomas. J Neurosurg 109(3):536-546, 2008.
  12. Fukai J, Yokote H, Yamanaka R, Arao T, Nishio K, Itakura T : EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol Cancer Ther 7(9):2768-2678, 2008.
  13. YamanakaR, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R: Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma 48(6):1119-1126, 2007.
  14. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, Sano M, Oide A, Sekijima M, Nishio K :Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25(44): 5994-6002, 2006.
  15. TsuchiyaN, YamanakaR, YajimaN, HommaJ, Sano M, KomataT, IkedaT, FujimotoI, TakahashiH, TanakaR, IkenakaK: Isolation and characterization of an N-Linked oligosaccharide that is increased in glioblastoma tissue and cell line. Int J Oncol 27(5):1231-1239, 2005.
  16. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R :  Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma.   Clin Cancer Res 11(16):5900-5911, 2005.
  17. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11(11):4160-4167, 2005.
TEL: 81-75-212-5429
e-mail: ryaman@koto.kpu-m.ac.jp


602-8566 Kyoto-shi, Kamigyo-ku Kajii-cho,
Kawaramachi-Hirokoji, JAPAN